ArticlePurinergic signalling2026
ATP-sensing DNA origami nanodevices for targeted modulation of purinergic signaling in inflammatory tissue injury.
Article in Purinergic signalling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pathophysiology of inflammatory illnesses is significantly influenced by purinergic signaling dysregulation, e.g., excessive extracellular ATP (exATP), yet current medication development efforts to inhibit purinergic receptors are inadequate. In a recent publication in Nature Communications, Li et al. [1] found that design and characterization of ATP-sensing DNA origami nanotubes (NTs) provide a novel method for metabolite sensing, utilizing ATP sensors and catalytic units (ENPP1/CD73). The innovative design led to reliable ATP binding and conversion to adenosine (ADO), supporting purinergic signaling modulation. Nanodevices (NDs) demonstrated effectiveness in sensing pathological exATP levels, crucial for purinergic receptor activation, significantly reducing cytokine expression and mitochondrial damage in immune cells. Monocyte-targeted ND delivery enhanced anti-inflammatory effects in acute lung and kidney injury models, showcasing superior therapeutic potential compared to unmodified NDs. RNA sequencing highlighted gene expression changes linked to inflammation, while metabolomic analysis showed improvements in mitochondrial function. The findings underscore the significance of purinergic signaling in inflammation and propose the DNA nanodevice as a promising therapeutic strategy, although challenges regarding stability and measurement remain to be addressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.